
    
      This study will be conducted in two parts. Part I of the study will be dose escalation
      evaluation to determine the MTD and/or RP2D of IMP4297 in combination with temozolomide. Part
      II of the study will be conducted in two RP2D expansion cohorts (sensitive ES-SCLC cohort and
      resistant ES-SCLC cohort) to further evaluate the anti-tumor activity, safety and
      tolerability of this regimen in ES-SCLC patients.
    
  